Pharma Access Framework

A medicine that is approved in one nation takes years to become approved and available worldwide due to an absence of a globally harmonized approval system. As a result, patients suffer or die needlessly while waiting for the medicine to reach their country. It is imperative that this change.

 

Therefore Medebound HEALTH strives to accelerate the introduction of breakthrough medicines from all over the world to meet patients' local unmet medical needs.

We see our role as bringing innovative global treatments to patients through multiple vehicles to fulfill our mission of expanding access to quality care across the globe. We invite biotech and biopharma companies interested in helping more patients who have no access to your medicines, to contact us.

Science Lab

Named Patient Access

We are dedicated to partnering with global biopharmaceutical companies to bring innovative medicines to the Asia Pacific using our expertise in clinical KOLs network, regulatory licences, and logistics handling.  

The process is based on a Named Patient import, in which patients acquire small amounts of medicine that will be used only for themselves to alleviate a troubling condition.  As a result, we can develop and manage an early access programme for biopharmaceutical companies to gain access to the Asian market through this method, regardless of whether or not they wish to obtain market authorization in these emerging markets. We provide the expertise, resources and technology to manage each and every individual request for these new medicines

Exclusive Distribution/In-License

With access to our in-house expertise and knowledge of international regulatory and legal frameworks in Asia, we will be able to help pharmaceutical companies gain market access which will not only generate early revenue for them but also provide them with real-world evidence (RWE) crucial to local regulatory approval. With our AI-enabled proprietary technology, we facilitate RWE access.  For the in-licensed products, we will lead all the clinical development.  Once it is legally registered in the target country, we will partner with national/regional pharmaceutical companies for commercialization. ​

Pharmacist

FAQs

What is a Named Patient program?


A Named Patient Program provides access to post-approval drugs that are approved and commercially available in one country other than patient's home country. The program enables healthcare professionals across the world to access new medicines, for patients who have no other treatment options available to them in their own countries,through a process known as the Personal Importation Process.




What are the advantages for companies of conducting a Named Patient program?


There are many advantages for biopharma companies with a newly approved medicine: - Managing unsolicited patient requests for drugs in an ethical and regulatory controlled manner - Building a stronger network of KOLs and future advocates by exposing physicians in new markets to your products - Providing benefits to patients suffering from conditions, including some that can be life-threatening. - Generating additional revenues in countries that allow you to charge for drugs supplied on a named patient basis




Can pharmaceutical companies provide drug to patients in any country?


Companies can provide drugs to patients in any country in which they have not yet received marketing authorization. This includes countries in which a company plans to seek marketing approval, as well as those countries in which a company does not plan to seek marketing approval. With a properly established Named Patient program, we help navigate the complex regulatory landscape, especially in Asia countries, and manage the shipment, customs clearance, and delivery to treating clinics.




How can I introduce Medebound HEALTH to a biopharma company?


We can share introduction materials or schedule a demo to learn more about our full range of offerings.




Why choose Medebound HEALTH to be your partner in Asia?


With access to our in-house expertise and knowledge of international regulatory and legal frameworks in Asia, we will be able to help pharmaceutical companies gain market access which will not only generate early revenue for them but also provide them with real-world evidence (RWE) crucial to local regulatory approval. In addition to helping your products reach key Asian markets, where we have significant network and in-depth industry and regulatory knowledge, we have developed a AI enabled proprietary software to conduct Real World Evidence (RWE) for a select segment of the population. Having this data will give you a regulatory advantage if you decide to obtain market approval for this population.